Keith Wheatley

Summary

Affiliation: University of Birmingham
Country: UK

Publications

  1. ncbi request reprint Be skeptical about unexpected large apparent treatment effects: the case of an MRC AML12 randomization
    Keith Wheatley
    Clinical Trials Unit, University of Birmingham, Park Grange, Edgbaston, Birmingham, United Kingdom
    Control Clin Trials 24:66-70. 2003
  2. pmc Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients
    Natalie J Ives
    Birmingham Clinical Trials Unit, University of Birmingham, Birmingham B15 2RR
    BMJ 329:593. 2004
  3. ncbi request reprint No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials
    Rosemary E Gale
    Department of Haematology, Royal Free and University College Medical School, London, UK
    Blood 106:3658-65. 2005
  4. ncbi request reprint Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials
    Anupama Rao
    Department of Haematology, Camelia Botnar Laboratories, Great Ormond Street Hospital for Children, London, UK
    Br J Haematol 132:576-83. 2006
  5. ncbi request reprint Long-term results of the MRC AML10 trial
    Alan K Burnett
    Department of Haematology, University of Wales College of Medicine, Heath Park, Cardiff, CF14 4XN, United Kingdom
    Clin Adv Hematol Oncol 4:445-51. 2006
  6. pmc Home-based reach-to-grasp training for people after stroke: study protocol for a feasibility randomized controlled trial
    Ailie J Turton
    Department of Allied Health Professions, University of the West of England, Bristol BS351NS, UK
    Trials 14:109. 2013
  7. pmc Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial
    Michael Walsh
    Departments of Medicine and Clinical Epidemiology and Biostatistics, Marian Wing, Division of Nephrology, McMaster University, St, Joseph s Hospital, 50 Charlton Ave East, Hamilton, ON L8S 4A6, Canada
    Trials 14:73. 2013
  8. pmc A cluster randomised controlled trial of an occupational therapy intervention for residents with stroke living in UK care homes (OTCH): study protocol
    Cath M Sackley
    Faculty of Medicine and Health Sciences, University of East Anglia, Norwich NR4 7TJ, UK
    BMC Neurol 12:52. 2012
  9. ncbi request reprint Randomized placebo-controlled trial of granulocyte colony stimulating factor (G-CSF) as supportive care after induction chemotherapy in adult patients with acute myeloid leukaemia: a study of the United Kingdom Medical Research Council Adult Leukaemia Wor
    Keith Wheatley
    Birmingham Clinical Trials Unit, School of Cancer Sciences, Robert Aitken Institute, University of Birmingham, Edgbaston, Birmingham, UK
    Br J Haematol 146:54-63. 2009
  10. ncbi request reprint Commentary: Mendelian randomization--an update on its use to evaluate allogeneic stem cell transplantation in leukaemia
    Keith Wheatley
    University of Birmingham Clinical Trials Unit, 1 Somerset Road, Birmingham B15 2RR, UK
    Int J Epidemiol 33:15-7. 2004

Collaborators

Detail Information

Publications51

  1. ncbi request reprint Be skeptical about unexpected large apparent treatment effects: the case of an MRC AML12 randomization
    Keith Wheatley
    Clinical Trials Unit, University of Birmingham, Park Grange, Edgbaston, Birmingham, United Kingdom
    Control Clin Trials 24:66-70. 2003
    ....
  2. pmc Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients
    Natalie J Ives
    Birmingham Clinical Trials Unit, University of Birmingham, Birmingham B15 2RR
    BMJ 329:593. 2004
    ..To quantify more reliably the benefits and risks of monoamine oxidase type B inhibitors (MAOBIs) in early Parkinson's disease...
  3. ncbi request reprint No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials
    Rosemary E Gale
    Department of Haematology, Royal Free and University College Medical School, London, UK
    Blood 106:3658-65. 2005
    ..70, CIs = 0.53-0.92; FLT3/ITD(+) OR = 0.59, CIs = 0.40-0.87; test for interaction, P = .5). These results suggest that at present there is no strong evidence that FLT3 status should influence the decision to proceed to transplantation...
  4. ncbi request reprint Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials
    Anupama Rao
    Department of Haematology, Camelia Botnar Laboratories, Great Ormond Street Hospital for Children, London, UK
    Br J Haematol 132:576-83. 2006
    ..56%, P = 0.02). Given the increased number of early treatment-related deaths, future treatment protocols should aim to reduce chemotherapy dosage or intensity whilst maintaining low rates of resistant and recurrent disease...
  5. ncbi request reprint Long-term results of the MRC AML10 trial
    Alan K Burnett
    Department of Haematology, University of Wales College of Medicine, Heath Park, Cardiff, CF14 4XN, United Kingdom
    Clin Adv Hematol Oncol 4:445-51. 2006
  6. pmc Home-based reach-to-grasp training for people after stroke: study protocol for a feasibility randomized controlled trial
    Ailie J Turton
    Department of Allied Health Professions, University of the West of England, Bristol BS351NS, UK
    Trials 14:109. 2013
    ....
  7. pmc Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial
    Michael Walsh
    Departments of Medicine and Clinical Epidemiology and Biostatistics, Marian Wing, Division of Nephrology, McMaster University, St, Joseph s Hospital, 50 Charlton Ave East, Hamilton, ON L8S 4A6, Canada
    Trials 14:73. 2013
    ..A randomized study of both plasma exchange and glucocorticoids is required to evaluate plasma exchange and oral glucocorticoid dosing in patients with AAV...
  8. pmc A cluster randomised controlled trial of an occupational therapy intervention for residents with stroke living in UK care homes (OTCH): study protocol
    Cath M Sackley
    Faculty of Medicine and Health Sciences, University of East Anglia, Norwich NR4 7TJ, UK
    BMC Neurol 12:52. 2012
    ....
  9. ncbi request reprint Randomized placebo-controlled trial of granulocyte colony stimulating factor (G-CSF) as supportive care after induction chemotherapy in adult patients with acute myeloid leukaemia: a study of the United Kingdom Medical Research Council Adult Leukaemia Wor
    Keith Wheatley
    Birmingham Clinical Trials Unit, School of Cancer Sciences, Robert Aitken Institute, University of Birmingham, Edgbaston, Birmingham, UK
    Br J Haematol 146:54-63. 2009
    ..There is some evidence from this trial of an adverse effect of G-CSF but these data need to be viewed in the context of the evidence from the other trials...
  10. ncbi request reprint Commentary: Mendelian randomization--an update on its use to evaluate allogeneic stem cell transplantation in leukaemia
    Keith Wheatley
    University of Birmingham Clinical Trials Unit, 1 Somerset Road, Birmingham B15 2RR, UK
    Int J Epidemiol 33:15-7. 2004
  11. doi request reprint Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials
    Keith Wheatley
    Birmingham Clinical Trials Unit, School of Cancer Sciences, Robert Aitken Institute, University of Birmingham, Edgbaston, Birmingham, UK
    Br J Haematol 145:598-605. 2009
    ..These risk groups apply to both intensively and non-intensively treated patients. Randomized trials of intensive versus non-intensive therapy are needed to determine which types of patient should be given which type of treatment...
  12. ncbi request reprint SAB--a promising new treatment to improve remission rates in AML in the elderly?
    Keith Wheatley
    University of Birmingham Clinical Trials Unit, Park Grange, 1 Somerset Road, Edgbaston, Birmingham B15 2RR, UK
    Br J Haematol 118:432-3. 2002
    ..This short report presents the results of a comparison of complete remission rates and reasons for failure, between two series of patients aged 60 years or over with acute myeloid leukaemia (AML), and discusses their interpretation...
  13. pmc Evaluating drug treatments for Parkinson's disease: how good are the trials?
    Keith Wheatley
    Birmingham Clinical Trials Unit, University of Birmingham, Birmingham B15 2RR, UK
    BMJ 324:1508-11. 2002
  14. ncbi request reprint Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation?--a statistician's view
    Keith Wheatley
    University of Birmingham Clinical Trials Unit, Park Grange, 1 Somerset Road, Edgbaston, Birmingham B15 2RR, UK
    Br J Haematol 118:351-6. 2002
  15. doi request reprint Physiotherapy versus placebo or no intervention in Parkinson's disease
    Claire L Tomlinson
    Birmingham Clinical Trials Unit, University of Birmingham, Robert Aitken Institute, Edgbaston, Birmingham, UK, B15 2TT
    Cochrane Database Syst Rev 9:CD002817. 2013
    ..The overall aim is to optimise independence, safety, and well-being, thereby enhancing quality of life...
  16. pmc Physiotherapy intervention in Parkinson's disease: systematic review and meta-analysis
    Claire L Tomlinson
    Birmingham Clinical Trials Unit, University of Birmingham, Birmingham B15 2TT, UK
    BMJ 345:e5004. 2012
    ..To assess the effectiveness of physiotherapy compared with no intervention in patients with Parkinson's disease...
  17. doi request reprint Physiotherapy versus placebo or no intervention in Parkinson's disease
    Claire L Tomlinson
    Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK
    Cochrane Database Syst Rev 8:CD002817. 2012
    ..The overall aim is to optimise independence, safety and well-being, thereby enhancing quality of life...
  18. ncbi request reprint Physiotherapy for Parkinson's disease: a comparison of techniques
    Claire L Tomlinson
    Birmingham Clinical Trials Unit, University of Birmingham, Robert Aitken Institute, Edgbaston, Birmingham, UK, B15 2TT
    Cochrane Database Syst Rev 6:CD002815. 2014
    ..Trials have shown that physiotherapy has short-term benefits in PD. However, which physiotherapy intervention is most effective remains unclear...
  19. doi request reprint Should treatment for Parkinson's disease start immediately on diagnosis or delayed until functional disability develops?
    Carl E Clarke
    Department of Neurology, City Hospital, Sandwell and West Birmingham NHS Trust, Dudley Road, Birmingham, United Kingdom
    Mov Disord 26:1187-93. 2011
    ....
  20. doi request reprint Meta-analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease
    Rebecca Stowe
    Birmingham Clinical Trials Unit, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, United Kingdom
    Mov Disord 26:587-98. 2011
    ..It is unclear whether one class of drug is more effective than another. This meta-analysis evaluates the comparative benefits and risks of these agents as adjuvant treatment in Parkinson's disease patients with motor complications...
  21. ncbi request reprint Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients
    Natalie J Ives
    Birmingham Clinical Trials Unit, Division of Medical Sciences, Robert Aitken Institute, University of Birmingham, Edgbaston, Birmingham, United Kingdom
    J Clin Oncol 25:5426-34. 2007
    ..The only subgroup analysis performed was by type of immunotherapy, with trials divided according to whether IFN only or IFN and IL-2 were administered in the biochemotherapy arm...
  22. doi request reprint Physiotherapy versus placebo or no intervention in Parkinson's disease
    Claire L Tomlinson
    Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK
    Cochrane Database Syst Rev 7:CD002817. 2012
    ..The overall aim is to optimise independence, safety and well-being, thereby enhancing quality of life...
  23. ncbi request reprint Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials
    Keith Wheatley
    University of Birmingham Clinical Trials Unit, Park Grange, 1 Somerset Road, Edgbaston, Birmingham, B15 2RR, UK
    Cancer Treat Rev 29:241-52. 2003
    ..The results of the individual trials have been either inconclusive or even apparently conflicting. To assess all the available evidence we performed a meta-analysis of these trials...
  24. doi request reprint Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial
    Annie M Young
    Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK
    Lancet 373:567-74. 2009
    ..We therefore assessed whether warfarin reduces catheter-related thrombosis compared with no warfarin and whether the dose of warfarin determines the thromboprophylactic effect...
  25. ncbi request reprint Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial
    Donald W Milligan
    Department of Haemotology, Birmingham Heartlands Hospital, Birmingham B9 5SS, UK
    Blood 107:4614-22. 2006
    ..In conclusion these findings indicate that FLA may be inferior to standard chemotherapy in high-risk AML and that the outcome is not improved with the addition of either G-CSF or ATRA...
  26. doi request reprint A randomised controlled trial of treatment for idiopathic intracranial hypertension
    Alexandra K Ball
    Department of Neurology, School of Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK
    J Neurol 258:874-81. 2011
    ..Clinical trials in IIH require pragmatic design to involve sufficiently large numbers of patients. Future studies should incorporate weighted composite scores to reflect the relative importance of common outcome measures in IIH...
  27. pmc Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial
    Adrian Williams
    Queen Elizabeth Hospital, Birmingham, Birmingham, UK
    Lancet Neurol 9:581-91. 2010
    ..We aimed to assess whether surgery and best medical therapy improved self-reported quality of life more than best medical therapy alone in patients with advanced Parkinson's disease...
  28. ncbi request reprint Continuing uncertainty about the value of percutaneous revascularization in atherosclerotic renovascular disease: a meta-analysis of randomized trials
    Natalie J Ives
    Birmingham Clinical Trials Unit, The University of Birmingham, Park Grange, 1 Somerset Road, Edgbaston, Birmingham B15 2RR, UK
    Nephrol Dial Transplant 18:298-304. 2003
    ..To study the effect of revascularization on blood pressure (BP) and serum creatinine (SCr) in patients with atherosclerotic renovascular disease (ARVD)...
  29. ncbi request reprint A systematic review of (131)I-meta iodobenzylguanidine molecular radiotherapy for neuroblastoma
    Jayne S Wilson
    Cancer Research UK Clinical Trials Unit, School of Cancer Sciences, University of Birmingham, Vincent Drive, Edgbaston, Birmingham B15 2TT, United Kingdom
    Eur J Cancer 50:801-15. 2014
    ..We conclude that (131)I-mIBG is an active treatment for neuroblastoma, but its place in the management of neuroblastoma remains unclear. Prospective randomised trials are essential to strengthen the evidence base. ..
  30. doi request reprint Calcineurin inhibitor sparing with mycophenolate in kidney transplantation: a systematic review and meta-analysis
    Jason Moore
    Department of Nephrology and Kidney Transplantation, Renal Institute of Birmingham, University Hospital Birmingham, Edgbaston, Birmingham, United Kingdom
    Transplantation 87:591-605. 2009
    ..In an attempt to aid clarification, we conducted a systematic review and meta-analysis of randomized trials that assessed CNI sparing (minimization or elimination) with mycophenolate as sole adjunctive immunosuppression...
  31. ncbi request reprint Interferon as adjuvant treatment for melanoma
    Keith Wheatley
    Lancet 360:878. 2002
  32. ncbi request reprint FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia
    Adam J Mead
    Department of Haematology, Royal Free and University College Medical School, London, United Kingdom
    Blood 110:1262-70. 2007
    ....
  33. ncbi request reprint A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment
    Alan K Burnett
    Department of Haematology, Wales School of Medicine, Cardiff University, Cardiff, United Kingdom
    Cancer 109:1114-24. 2007
    ..The survival of older patients with acute myeloid leukemia has not improved. Few clinical trials have been available for older patients who are not considered fit for an intensive chemotherapy approach...
  34. ncbi request reprint Problems with up-front randomization in clinical trials
    Keith Wheatley
    J Clin Oncol 24:5471-2; author reply 5472-3. 2006
  35. ncbi request reprint The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial
    Alan K Burnett
    Department of Haematology, University of Wales College of Medicine, Heath Park, Cardiff CF14 4XN, Wales, UK
    Br J Haematol 118:385-400. 2002
    ..This trial found no survival advantage in children, patients over 35 years or good-risk disease...
  36. ncbi request reprint Need for a quantitative meta-analysis of trials of adjuvant interferon in melanoma
    Keith Wheatley
    J Clin Oncol 20:4120-1; author reply 4121-2. 2002
  37. ncbi request reprint High-dose chemotherapy and stem cell transplantation does not improve relapse-free or overall survival in women with high-risk breast cancer
    Robert W Carlson
    Stanford University, Stanford, CA, USA
    Cancer Treat Rev 30:131-7. 2004
  38. ncbi request reprint Cabergoline versus levodopa monotherapy
    Keith Wheatley
    Mov Disord 19:733-4; author reply 734-5. 2004
  39. ncbi request reprint Fludarabine, cytosine arabinoside, granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes
    Donald W Milligan
    Br J Haematol 127:238-9. 2004
  40. ncbi request reprint Adjuvant interferon therapy for melanoma
    Barry Hancock
    J Clin Oncol 23:2431; author reply 2431-2. 2005
  41. ncbi request reprint Del (9q) AML: clinical and cytological characteristics and prognostic implications
    Andrew Peniket
    Leukaemia Research Fund Molecular Haematology Unit, John Radcliffe Hospital, Oxford, UK
    Br J Haematol 129:210-20. 2005
    ..It is likely that the deletion of single or multiple tumour suppressor genes located in this region may underlie the pathogenesis of del (9q) AML...
  42. ncbi request reprint RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years
    David T Bowen
    Division of Pathology and Neuroscience, Ninewells Hospital, Dundee DD1 9SY, United Kingdom
    Blood 106:2113-9. 2005
    ..RAS mutation did not influence clinical outcome (overall/disease-free survival, complete remission, relapse rate) either for the entire cohort or within cytogenetic risk groups...
  43. ncbi request reprint Results of treatment of children with refractory anaemia with excess blasts (RAEB) and RAEB in transformation (RAEBt) in Great Britain 1990-99
    David K H Webb
    Great Ormond Street Hospital for Children, London, Clinical Trial Service Unit, Oxford, UK
    Br J Haematol 117:33-9. 2002
    ..05). Allowing for cytogenetics, outcomes of therapy appear similar to those for de novo acute myeloid leukaemia (AML), and it is appropriate for children with RAEB/RAEBt to be registered in AML trials...
  44. ncbi request reprint Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia
    Rosemary E Gale
    Department of Haematology, University College London Hospitals, United Kingdom
    Blood 106:3768-76. 2005
    ..Furthermore, in the presence of CEP-701, ATRA-induced differentiation was reduced in FLT3/ITD+ cells. These data carry implications for the use of FLT3 inhibitors as frontline therapy for APL...
  45. ncbi request reprint Priority-setting decisions for new cancer drugs
    Keith Wheatley
    Lancet 359:1525. 2002
  46. ncbi request reprint Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes
    Bridget S Wilkins
    Department of Cellular Pathology, Newcastle upon Tyne Hospitals National Health Service NHS Foundation Trust and Newcastle University, Newcastle upon Tyne, UK
    Blood 111:60-70. 2008
    ..This study was registered at http://isrctn.org as #72251782 and at http://eudract.emea.europa.eu/ as #2004-000245-38...
  47. ncbi request reprint Does adjuvant vaccine therapy really have activity in malignant melanoma?
    Keith Wheatley
    J Clin Oncol 25:4693; author reply 4693-5. 2007
  48. pmc Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials
    Dwomoa Adu
    Department of Nephrology, Queen Elizabeth Hospital, Birmingham, B15 2TH
    BMJ 326:789. 2003
    ..To study the effect of interleukin-2 receptor monoclonal antibodies on acute rejection episodes, graft loss, deaths, and rate of infection and malignancy in patients with renal transplants...
  49. ncbi request reprint High-dose chemotherapy for breast cancer
    Keith Wheatley
    N Engl J Med 349:1476-9; author reply 1476-9. 2003
  50. ncbi request reprint ICON4/AGO-OVAR-2.2: questions about trial design, cost-effectiveness, and clinical benefit
    Keith Wheatley
    Lancet 362:1333; author reply 1334. 2003
  51. ncbi request reprint Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia
    Claire N Harrison
    Department of Haematology, University of Cambridge, and Addenbrooke s National Health Service Trust, Cambridge, United Kingdom
    N Engl J Med 353:33-45. 2005
    ..We conducted a randomized comparison of hydroxyurea with anagrelide in the treatment of essential thrombocythemia...